FOI 5428-Diagnosis of Multiple Sclerosis

Date: 04 November 2019 to 04 November 2022

  1. In your trust how many patients have a diagnosis of Multiple Sclerosis (MS), regardless of whether they are currently on treatment?
  2. Of these MS patients, how many have been diagnosed with relapsing (RMS) or primary progressive (PPMS) MS;

>RMS >PPMS

>Not known

 

  1. How many patients with Multiple Sclerosis have been treated with disease modifying drugs in the past 6 months. Please include all patients whose treatment is ongoing,  even those with infrequent dosing schedules (e.g. Lemtrada, Mavenclad, Ocrevus). Please provide the total number of patients by treatment for the following disease modifying drugs:

 

Aubagio (teriflunomide)   Avonex (interferon beta-1a)   Betaferon (interferon beta-1b)   Brabio (glatiramer acetate) 

Copaxone (glatiramer acetate)  

Extavia (beta interferon-1b)  

Gilenya (fingolimod)  

Lemtrada (alemtuzumab)  

Mavenclad (cladribine) 

Ocrevus (Ocrelizumab) 

Plegridy (Peginterferon beta-1a) 

Rebif (beta interferon-1a)  

Tecfidera (dimethyl fumarate)  

Tysabri (natalizumab)  

Zinbryta (daclizumab) 

Ampyra (Fampyra) 

  • Request ID:
    FOI 5428
  • Category:
    Clinical - Drugs
  • Response:

    Response attached